[{"address1": "80 Guest Street", "address2": "Suite 601", "city": "Boston", "state": "MA", "zip": "02135", "country": "United States", "phone": "617 500 8099", "website": "https://www.compasstherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; and CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies. It also develops CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A; and VEGF-IO Bispecific / Multiple, a bispecific antibody engages the angiogenesis pathway and anti-tumor immune that targets, including immune checkpoints, as well as analyzes VEGF combinations with other immune response-related proteins. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 35, "companyOfficers": [{"maxAge": 1, "name": "Dr. Thomas J. Schuetz M.D., Ph.D.", "age": 63, "title": "Chief Executive Officer", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 835875, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Vered  Bisker-Leib MBA, Ph.D.", "age": 53, "title": "Advisor", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 719000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Barry  Shin J.D.", "age": 52, "title": "Chief Financial Officer", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Neil L. Lerner CPA", "age": 57, "title": "Senior VP & Chief Accounting Officer", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jonathan  Anderman J.D.", "title": "Senior Vice President, General Counsel & Corporate Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Anna  Gifford", "title": "Communications Manager", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Minori  Rosales M.D., Ph.D.", "age": 61, "title": "Senior VP & Head of Clinical Development", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karin  Herrera B.A.", "title": "Senior VP & Head of Clinical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James  Kranz Ph.D.", "title": "VP and Head of Chemistry Manufacturing & Controls", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.12, "open": 2.11, "dayLow": 1.91, "dayHigh": 2.15, "regularMarketPreviousClose": 2.12, "regularMarketOpen": 2.11, "regularMarketDayLow": 1.91, "regularMarketDayHigh": 2.15, "payoutRatio": 0.0, "beta": 1.187, "forwardPE": -3.8039217, "volume": 870780, "regularMarketVolume": 870780, "averageVolume": 1587360, "averageVolume10days": 717950, "averageDailyVolume10Day": 717950, "bid": 1.93, "ask": 1.97, "bidSize": 1, "askSize": 2, "marketCap": 293159200, "fiftyTwoWeekLow": 0.765, "fiftyTwoWeekHigh": 4.08, "priceToSalesTrailing12Months": 344.8932, "fiftyDayAverage": 2.3245, "twoHundredDayAverage": 1.862155, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 148180048, "profitMargins": 0.0, "floatShares": 91483552, "sharesOutstanding": 138282000, "sharesShort": 6618254, "sharesShortPriorMonth": 3695821, "sharesShortPreviousMonthDate": 1740700800, "dateShortInterest": 1743379200, "sharesPercentSharesOut": 0.0479, "heldPercentInsiders": 0.18077, "heldPercentInstitutions": 0.66206, "shortRatio": 7.49, "shortPercentOfFloat": 0.0675, "impliedSharesOutstanding": 151112992, "bookValue": 0.909, "priceToBook": 2.1342134, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -49375000, "trailingEps": -0.36, "forwardEps": -0.51, "enterpriseToRevenue": 174.329, "enterpriseToEbitda": -2.644, "52WeekChange": 0.32876718, "SandP52WeekChange": 0.07995045, "quoteType": "EQUITY", "currentPrice": 1.94, "targetHighPrice": 32.0, "targetLowPrice": 6.0, "targetMeanPrice": 13.1, "targetMedianPrice": 10.5, "recommendationMean": 1.3, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 10, "totalCash": 126722000, "totalCashPerShare": 0.916, "ebitda": -56036000, "totalDebt": 6634000, "quickRatio": 14.28, "currentRatio": 14.96, "totalRevenue": 850000, "debtToEquity": 5.297, "revenuePerShare": 0.006, "returnOnAssets": -0.23809999, "returnOnEquity": -0.3607, "grossProfits": 850000, "freeCashflow": -27798624, "operatingCashflow": -44855000, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -66.61765, "financialCurrency": "USD", "symbol": "CMPX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1617629400000, "postMarketChangePercent": -1.03093, "postMarketPrice": 1.92, "postMarketChange": -0.0200001, "regularMarketChange": -0.17999983, "regularMarketDayRange": "1.91 - 2.15", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 1587360, "fiftyTwoWeekLowChange": 1.1750001, "fiftyTwoWeekLowChangePercent": 1.5359478, "fiftyTwoWeekRange": "0.765 - 4.08", "fiftyTwoWeekHighChange": -2.1399999, "fiftyTwoWeekHighChangePercent": -0.5245098, "fiftyTwoWeekChangePercent": 32.876717, "earningsTimestamp": 1740663000, "earningsTimestampStart": 1747053000, "earningsTimestampEnd": 1747485000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.36, "epsForward": -0.51, "epsCurrentYear": -0.46667, "priceEpsCurrentYear": -4.157113, "fiftyDayAverageChange": -0.38450003, "fiftyDayAverageChangePercent": -0.16541192, "twoHundredDayAverageChange": 0.0778451, "twoHundredDayAverageChangePercent": 0.04180377, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-11-02", "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1745618686, "regularMarketTime": 1745611201, "exchange": "NCM", "messageBoardId": "finmb_266166780", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "shortName": "Compass Therapeutics, Inc.", "longName": "Compass Therapeutics, Inc.", "regularMarketChangePercent": -8.490559, "regularMarketPrice": 1.94, "marketState": "CLOSED", "displayName": "Compass Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-04-26"}]